These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28692770)

  • 21. Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care.
    Ørnbjerg LM; Rugbjerg K; Georgiadis S; Rasmussen SH; Jacobsson L; Loft AG; Iannone F; Fagerli KM; Vencovsky J; Santos MJ; Möller B; Pombo-Suarez M; Rotar Z; Gudbjornsson B; Cefle A; Eklund K; Codreanu C; Jones G; van der Sande M; Wallman JK; Sebastiani M; Michelsen B; Závada J; Nissen MJ; Sanchez-Piedra C; Tomšič M; Love TJ; Relas H; Mogosan C; Hetland ML; Østergaard M
    J Rheumatol; 2024 Apr; 51(4):378-389. PubMed ID: 38224992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Necessity of TNF-alpha inhibitor discontinuation in rheumatoid arthritis is predicted by smoking and number of previously used biological DMARDs.
    Cuppen BV; Jacobs JW; Ter Borg EJ; Marijnissen AC; Bijlsma JW; Lafeber FP; van Laar JM;
    Clin Exp Rheumatol; 2017; 35(2):221-228. PubMed ID: 27749223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
    Chastek B; Chen CI; Proudfoot C; Shinde S; Kuznik A; Wei W
    Adv Ther; 2017 Nov; 34(11):2422-2435. PubMed ID: 29039054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial.
    Manders SH; Kievit W; Adang E; Brus HL; Moens HJ; Hartkamp A; Hendriks L; Brouwer E; Visser H; Vonkeman HE; Hendrikx J; Jansen TL; Westhovens R; van de Laar MA; van Riel PL
    Arthritis Res Ther; 2015 May; 17(1):134. PubMed ID: 25997746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial.
    van Herwaarden N; van der Maas A; Minten MJ; van den Hoogen FH; Kievit W; van Vollenhoven RF; Bijlsma JW; van den Bemt BJ; den Broeder AA
    BMJ; 2015 Apr; 350():h1389. PubMed ID: 25858265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determinants associated with work participation in patients with established rheumatoid arthritis taking tumor necrosis factor inhibitors.
    Manders SH; Kievit W; Braakman-Jansen AL; Brus HL; Hendriks L; Fransen J; van de Laar MA; van Riel PL
    J Rheumatol; 2014 Jul; 41(7):1263-9. PubMed ID: 24833758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perceived work ability, quality of life, and fatigue in patients with rheumatoid arthritis after a 6-month course of TNF inhibitors: prospective intervention study and partial economic evaluation.
    Hoving JL; Bartelds GM; Sluiter JK; Sadiraj K; Groot I; Lems WF; Dijkmans BA; Wijbrandts CA; Tak PP; Nurmohamed MT; Voskuyl AE; Frings-Dresen MH
    Scand J Rheumatol; 2009; 38(4):246-50. PubMed ID: 19337948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful cessation of tumor necrosis factor inhibitor treatment in rheumatoid arthritis patients and potential predictors for early flare: An observational study in routine clinical care.
    Naniwa T; Iwagaitsu S; Kajiura M
    Mod Rheumatol; 2020 Nov; 30(6):948-958. PubMed ID: 31814481
    [No Abstract]   [Full Text] [Related]  

  • 29. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders?
    Ibrahim F; Lorente-Cánovas B; Doré CJ; Bosworth A; Ma MH; Galloway JB; Cope AP; Pande I; Walker D; Scott DL
    Rheumatology (Oxford); 2017 Nov; 56(11):2004-2014. PubMed ID: 28968858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Juvenile Idiopathic Arthritis or Rheumatoid Arthritis.
    Lee WJ; Briars L; Lee TA; Calip GS; Suda KJ; Schumock GT
    Pharmacotherapy; 2016 Dec; 36(12):1201-1209. PubMed ID: 27779782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current concepts in the management of rheumatoid arthritis.
    Tanaka Y
    Korean J Intern Med; 2016 Mar; 31(2):210-8. PubMed ID: 26932398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial.
    Strand V; Burmester GR; Zerbini CA; Mebus CA; Zwillich SH; Gruben D; Wallenstein GV
    Arthritis Care Res (Hoboken); 2015 Apr; 67(4):475-83. PubMed ID: 25186034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Flare Rate in Patients with Rheumatoid Arthritis in Low Disease Activity or Remission When Tapering or Stopping Synthetic or Biologic DMARD: A Systematic Review.
    Kuijper TM; Lamers-Karnebeek FB; Jacobs JW; Hazes JM; Luime JJ
    J Rheumatol; 2015 Nov; 42(11):2012-22. PubMed ID: 26428204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploring TNFi drug-levels and anti-drug antibodies during tapering among patients with inflammatory arthritis: secondary analyses from the randomised BIODOPT trial.
    Uhrenholt L; Sørensen MER; Lauridsen KB; Duch K; Dreyer L; Christensen R; Hauge EM; Loft AG; Rasch MNB; Horn HC; Taylor PC; Nielsen KR; Kristensen S
    Rheumatol Int; 2024 Oct; 44(10):1897-1908. PubMed ID: 39043980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis.
    Chastek B; Becker LK; Chen CI; Mahajan P; Curtis JR
    J Med Econ; 2017 May; 20(5):464-473. PubMed ID: 28010149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial.
    Lillegraven S; Paulshus Sundlisæter N; Aga AB; Sexton J; Olsen IC; Lexberg ÅS; Madland TM; Fremstad H; Høili CA; Bakland G; Spada C; Haukeland H; Hansen IM; Moholt E; Uhlig T; Solomon DH; van der Heijde D; Kvien TK; Haavardsholm EA
    Ann Rheum Dis; 2023 Nov; 82(11):1394-1403. PubMed ID: 37607809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis.
    Sauer BC; Teng CC; Tang D; Leng J; Curtis JR; Mikuls TR; Harrison DJ; Cannon GW
    Arthritis Care Res (Hoboken); 2017 Mar; 69(3):313-322. PubMed ID: 27273801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term outcomes of treat-to-target strategy in established rheumatoid arthritis: a daily practice prospective cohort study.
    de Andrade NPB; da Silva Chakr RM; Xavier RM; Viecceli D; Correa RHB; de Oliveira Filho CM; Brenol CV
    Rheumatol Int; 2017 Jun; 37(6):993-997. PubMed ID: 28293776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry.
    Kavanaugh A; Lee SJ; Curtis JR; Greenberg JD; Kremer JM; Soto L; Etzel CJ; Cox V; Yoshida K; Reed GW; Solomon DH
    Ann Rheum Dis; 2015 Jun; 74(6):1150-5. PubMed ID: 25471471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimizing biological treatment in rheumatoid arthritis with the aid of therapeutic drug monitoring.
    Eng GP
    Dan Med J; 2016 Nov; 63(11):. PubMed ID: 27808043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.